5f4n
From Proteopedia
(New page: '''Unreleased structure''' The entry 5f4n is ON HOLD Authors: Collins, I., Garrett, M.D., van Montfort, R., Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.J., Lainchb...) |
m (Protected "5f4n" [edit=sysop:move=sysop]) |
Revision as of 12:37, 9 December 2015
Unreleased structure
The entry 5f4n is ON HOLD
Authors: Collins, I., Garrett, M.D., van Montfort, R., Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.J., Lainchbury, M., Brown, N., Walton, M.I., Eve, P.D., Boxall, K.J., Hayes, A., Henley, A.T., Valenti, M.R., De Haven Brandon, A.K., Box, G., Westwood, I.M., Jamin, Y., Robinson, S.P., Leonard, P., Reader, J.C., Aherne, G.W., Raynaud, F.I., Eccles, S.A.
Description: Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
Categories: Unreleased Structures | Mchardy, T | Cheung, K.J | Hayes, A | Lainchbury, M | Proisy, N | Collins, I | Westwood, I.M | Henley, A.T | Reader, J.C | Aherne, G.W | Raynaud, F.I | Eccles, S.A | Box, G | De Haven Brandon, A.K | Walton, M.I | Robinson, S.P | Jamin, Y | Van Montfort, R | Brown, N | Leonard, P | Eve, P.D | Valenti, M.R | Boxall, K.J | Osborne, J.D | Garrett, M.D | Matthews, T.P
